Home    Back

Mesenchymal stem cells isolated from wharton's jelly    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis1

2. Amyotrophic lateral sclerosis    [ 508 clinical trials,   530 drugs,   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways]
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 508 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04651855
(ClinicalTrials.gov)		December 2, 202030/9/2020The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALSThe Evaluation of the Effect of Wharton's Jelly Mesenchymal Stem Cells (WJMSCs) on the Immune System of Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: Mesenchymal stem cells isolated from Wharton's jellyPolski Bank Komorek Macierzystych JSC (PBKM)The National Centre for Research and DevelopmentRecruiting18 YearsN/AAll20Phase 1;Phase 2Poland